PMID- 32033147
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 2
DP  - 2020 Feb 4
TI  - Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been 
      Switched from Pirfenidone Therapy: A Retrospective Case Series Study.
LID - 10.3390/jcm9020422 [doi]
LID - 422
AB  - BACKGROUND: The efficacy and effectiveness of nintedanib as a first-line therapy 
      in idiopathic pulmonary fibrosis (IPF) patients have been demonstrated by 
      clinical trials and real-life studies. Our aim was to examine the safety profile 
      and effectiveness of nintedanib when it is utilized as a second-line treatment in 
      subjects who have discontinued pirfenidone. METHODS: The medical charts of 12 
      patients who were switched from pirfenidone to nintedanib were examined 
      retrospectively. The drug's safety was defined by the number of adverse events 
      (AEs) that were reported; disease progression was evaluated based on the 
      patient's vital status and changes in forced vital capacity (FVC) at 12-month 
      follow-up. RESULTS: The numbers of patients experiencing AEs and of the AEs per 
      patient in our study group didn't significantly differ with respect to a group of 
      56 individuals who were taking nintedanib as a first-line therapy during the 
      study period (5/12 vs. 22/56; p = 0.9999, and 0.00 (0.00-1.00) vs. 0.00 
      (0.00-3.00); p = 0.517, respectively). Two out of the 3 patients who had been 
      switched to nintedanib due to a rapid disease progression showed stabilized FVC 
      values. CONCLUSIONS: Nintedanib was found to have an acceptable safety profile in 
      the majority of the IPF patients switched from pirfenidone. Prospective studies 
      are warranted to determine if the drug can effectively delay disease progression 
      in these patients.
FAU - Vianello, Andrea
AU  - Vianello A
AD  - Respiratory Pathophysiology Unit, Dept. of Cardiological, Thoracic and Vascular 
      Sciences, University of Padova, 35128 Padova, Italy.
FAU - Salton, Francesco
AU  - Salton F
AD  - Pneumology Unit, Dept. of Medical, Surgical and Health Sciences, University of 
      Trieste, 34149 Trieste, Italy.
FAU - Molena, Beatrice
AU  - Molena B
AD  - Respiratory Pathophysiology Unit, Dept. of Cardiological, Thoracic and Vascular 
      Sciences, University of Padova, 35128 Padova, Italy.
FAU - Turato, Cristian
AU  - Turato C
AD  - Veneto Institute of Oncology IOV - IRCCS, 35128 Padova, Italy.
FAU - Graziani, Maria Laura
AU  - Graziani ML
AD  - Pneumology Unit, Dept. of Medical, Surgical and Health Sciences, University of 
      Trieste, 34149 Trieste, Italy.
FAU - Braccioni, Fausto
AU  - Braccioni F
AD  - Respiratory Pathophysiology Unit, Dept. of Cardiological, Thoracic and Vascular 
      Sciences, University of Padova, 35128 Padova, Italy.
FAU - Frassani, Valeria
AU  - Frassani V
AD  - Pneumology Unit, Arco General Hospital, APSS Trento, 38062 Arco, Italy.
FAU - Sella, Dino
AU  - Sella D
AD  - Pneumology Unit, Trento General Hospital, Trento, APSS Trento, 38121 Trento, 
      Italy.
FAU - Pretto, Paolo
AU  - Pretto P
AD  - Pulmonology Unit, AS Bolzano, 39100 Bolzano, Italy.
FAU - Paladini, Luciana
AU  - Paladini L
AD  - Respiratory Pathophysiology Unit, Dept. of Cardiological, Thoracic and Vascular 
      Sciences, University of Padova, 35128 Padova, Italy.
FAU - Sukthi, Andi
AU  - Sukthi A
AD  - Respiratory Pathophysiology Unit, Dept. of Cardiological, Thoracic and Vascular 
      Sciences, University of Padova, 35128 Padova, Italy.
FAU - Confalonieri, Marco
AU  - Confalonieri M
AD  - Pneumology Unit, Dept. of Medical, Surgical and Health Sciences, University of 
      Trieste, 34149 Trieste, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200204
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7074103
OTO - NOTNLM
OT  - Idiopathic pulmonary fibrosis
OT  - Nintedanib
OT  - Pirfenidone
OT  - adverse event
OT  - forced vital capacity
COIS- All the authors declare that they do not have any potential or actual conflicts 
      of interest including financial or personal relationships with persons or 
      organizations that could have inappropriately influenced (biased) the study. No 
      study sponsor was involved in designing or conceptualizing the study, in 
      collecting, analyzing/interpreting the data, in drafting the manuscript or in the 
      decision to submit the manuscript for publication.
EDAT- 2020/02/09 06:00
MHDA- 2020/02/09 06:01
PMCR- 2020/02/04
CRDT- 2020/02/09 06:00
PHST- 2020/01/04 00:00 [received]
PHST- 2020/02/01 00:00 [revised]
PHST- 2020/02/03 00:00 [accepted]
PHST- 2020/02/09 06:00 [entrez]
PHST- 2020/02/09 06:00 [pubmed]
PHST- 2020/02/09 06:01 [medline]
PHST- 2020/02/04 00:00 [pmc-release]
AID - jcm9020422 [pii]
AID - jcm-09-00422 [pii]
AID - 10.3390/jcm9020422 [doi]
PST - epublish
SO  - J Clin Med. 2020 Feb 4;9(2):422. doi: 10.3390/jcm9020422.